Use case | Description | Target population | Comments |
---|---|---|---|
(1) Travellers | Residents of regions of very low or no malaria incidence travelling to malaria endemic areas | Initially, all adults and children > 5 years | Increasing numbers of travellers within Africa, given increased GDP; increasing numbers of Africans in areas of low transmission |
(2a) Malaria epidemic | Re-emergence of malaria in zones which had been previously declared malaria free | Entire population | Need demonstration of safety in first trimester of pregnancy; deployment during ‘maintaining zero’ |
(2b) Febrile epidemic | Protection of a population from malaria during epidemics such as Ebola | Entire population | Need demonstration of safety in first trimester of pregnancy. Currently maintained as monthly ACT. Value only if injections offer longer protection |
(3) Protection from infection of subjects in high transmission zones | Replacing the SMC regimens of monthly protection by SP-AQ given currently to children under 5 in the Sahel with true chemoprotection | Children < 10 years | No requirement for safety demonstration in first trimester of pregnancy; combination would ideally have causal prophylaxis (preventing blood-stage and liver stage activity) |